In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

Lung cancer has a poor prognosis; over half of people diagnosed with lung cancer die
within one year of diagnosis and the 5-year survival is less than 18%. Non-small cell lung …

Purpose Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune
checkpoint inhibitor antibody, has demonstrated improved survival in previously treated …

Purpose Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody,
has demonstrated improved survival over docetaxel in previously treated advanced non …

Molecular targeted therapy heralded a new era for the treatment of patients with oncogene-
driven advanced-stage non–small-cell lung cancer (NSCLC). Molecular testing at the time of …

Purpose Cisplatin plus gemcitabine is a standard regimen for first-line treatment of
advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus …

Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in
specimens from patients with non–small-cell lung cancer who have a response to …

Abstract On June 22, 2017, the Food and Drug Administration expanded indications for
dabrafenib and trametinib to include treatment of patients with metastatic non‐small cell lung …

Chemotherapy-induced neutropaenia is a major risk factor for infection-related morbidity
and mortality and also a significant dose-limiting toxicity in cancer treatment. Patients …